Halozyme Therapeutics Inc., of San Diego, said the FDA granted orphan drug designation to pegylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Halozyme is currently investigating PEGPH20 in a phase II study in combination with gemcitabine and Abraxane (nab-paclitaxel, Celgene Corp.) in metastatic pancreatic cancer.